×
About 19,750 results

ALLMedicine™ Amyloidosis Center

Research & Reviews  9,503 results

Amyloid cystic lung disease presenting in a patient with human immunodeficiency virus.
https://doi.org/10.5603/ARM.a2021.0007
Advances in Respiratory Medicine; El-Baba FM, Banavasi H et. al.

Apr 19th, 2021 - A 30-year-old gentleman with a medical history of HIV, on HAART therapy and pulmonary amyloidosis proven by lung biopsy presented with progressive, worsening shortness of breath and chronic productive cough over the last year. Pulmonary function t...

Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiar...
https://doi.org/10.1016/j.ijcard.2021.04.023
International Journal of Cardiology; Zampieri M, Nardi G et. al.

Apr 18th, 2021 - Amyloidosis is considered a rare heterogeneous condition comprising different entities. Epidemiological data are limited and often controversial. We aimed to examine epidemiological changes in amyloidosis diagnosed over a 20-year period at a terti...

Paraproteinemias and Peripheral Nerve Disease.
https://doi.org/10.1016/j.cger.2021.01.004
Clinics in Geriatric Medicine; Leavell Y, Shin SC

Apr 16th, 2021 - This article provides an overview of the clinical features, diagnosis, and treatment of the major paraprotein-related peripheral neuropathies, including monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, POEMS syndr...

see more →

Guidelines  13 results

Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis
https://www.nature.com/articles/s41598-020-75433-7
Scientific Reports; Romano, M. et. al.

Oct 26th, 2020 - Chronic inflammation and proteinuria is a risk factor for cardiovascular disease (CVD) in patients with chronic kidney diseases and rheumatologic disorders. Our aim was to investigate the CVD events (CVDEs) and survival between the patients with F...

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement...
https://doi.org/10.1016/j.cjca.2019.12.034
The Canadian Journal of Cardiology; Fine NM, Davis MK et. al.

Mar 8th, 2020 - Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is caused by deposition of misfolded precursor proteins as fibrillary amyloid deposits in cardiac tissues. The two ...

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgita...
https://doi.org/10.1016/j.cjca.2019.11.036
The Canadian Journal of Cardiology; O'Meara E, McDonald M et. al.

Feb 9th, 2020 - In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provid...

2019 HRS expert consensus statement on evaluation, risk stratification, and management ...
https://doi.org/10.1016/j.hrthm.2019.05.007
Heart Rhythm; Towbin JA, McKenna WJ et. al.

May 12th, 2019 - Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders....

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0023
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.

Feb 11th, 2017 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-r...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  9,831 results

Amyloid cystic lung disease presenting in a patient with human immunodeficiency virus.
https://doi.org/10.5603/ARM.a2021.0007
Advances in Respiratory Medicine; El-Baba FM, Banavasi H et. al.

Apr 19th, 2021 - A 30-year-old gentleman with a medical history of HIV, on HAART therapy and pulmonary amyloidosis proven by lung biopsy presented with progressive, worsening shortness of breath and chronic productive cough over the last year. Pulmonary function t...

Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiar...
https://doi.org/10.1016/j.ijcard.2021.04.023
International Journal of Cardiology; Zampieri M, Nardi G et. al.

Apr 18th, 2021 - Amyloidosis is considered a rare heterogeneous condition comprising different entities. Epidemiological data are limited and often controversial. We aimed to examine epidemiological changes in amyloidosis diagnosed over a 20-year period at a terti...

Paraproteinemias and Peripheral Nerve Disease.
https://doi.org/10.1016/j.cger.2021.01.004
Clinics in Geriatric Medicine; Leavell Y, Shin SC

Apr 16th, 2021 - This article provides an overview of the clinical features, diagnosis, and treatment of the major paraprotein-related peripheral neuropathies, including monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, POEMS syndr...

see more →

News  329 results

More Evidence That Gum Disease May Play a Role in Alzheimer's Disease
https://www.medscape.com/viewarticle/949263

Apr 14th, 2021 - NEW YORK (Reuters Health) - Older cognitively healthy adults with more harmful than healthy bacteria in their gums are more likely to have biomarkers of amyloidosis in their cerebrospinal fluid (CSF), a new study has found. "Amyloid-beta in brain ...

Did Unrecognized Cardiac Amyloidosis Hinder Recent HFpEF Trials?
https://www.medscape.com/viewarticle/945394

Feb 4th, 2021 - Screening for cardiac amyloidosis and excluding patients with cardiac amyloidosis from trials of new therapies for heart failure with preserved ejection fraction (HFpEF) may increase the chances of finding drugs that actually work, a new analysis ...

FDA Approves First and Only Treatment for AL Amyloidosis
https://www.medscape.com/viewarticle/944380

Jan 19th, 2021 - The first and only treatment for a rare and often fatal blood cell disorder has been approved in the United States. The new indication is newly diagnosed light-chain (AL) amyloidosis, which affects about 4500 people in the United States each year....

Positive Data on Vutrisiran in hATTR Amyloidosis With Polyneuropathy
https://www.medscape.com/viewarticle/943863

Jan 7th, 2021 - The investigational RNAi therapeutic vutrisiran (Alnylam Pharmaceuticals) met its primary and secondary endpoints in a phase 3 study of adults with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy. Topline results from the...

TTR V122I Variant Linked to Adverse Cardiac Mechanics in Middle-Aged Black Americans
https://www.medscape.com/viewarticle/943531

Jan 4th, 2021 - NEW YORK (Reuters Health) - Echocardiographic screening of middle-aged U.S. Blacks revealed a significant association between the V122I transthyretin amyloidosis genetic variant (TTR V122I) and worse cardiac structure and function, possibly porten...

see more →

Patient Education  59 results see all →